TY  - JOUR
AB  - Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many cancer types. However, most patients do not respond to immunotherapies or relapse after an initial response, stressing the need for improved strategies. Chemokines, as mediators of immune cell trafficking, play an important role in the composition of the tumor microenvironment and exert both pro- and antitumorigenic functions. Here, chemokines may represent valuable prognostic biomarkers of response to immunotherapy and a strategy to improve immunotherapies. In this review, the pleiotropic functions of chemokines in the tumor microenvironment (TME) and strategies of utilizing chemokines or chemokine antagonism in immunotherapy are discussed. The review highlights preclinical and clinical studies that apply or target chemokines in monotherapy or in combination therapies.
AU  - Märkl, F.*
AU  - Huynh, D.*
AU  - Endres, S.
AU  - Kobold, S.
C1  - 65030
C2  - 52143
SP  - 670-682
TI  - Utilizing chemokines in cancer immunotherapy.
JO  - Trends Cancer
VL  - 8
IS  - 8
PY  - 2022
SN  - 2405-8033
ER  - 

TY  - JOUR
AB  - Immune regulation has an important role in cancer development, particularly in organs with continuous exposure to environmental pathogens, such as the liver and gastrointestinal tract. Chronic liver inflammation can lead to the development of hepatobiliary cancers, namely hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), or combined HCC (cHCC)-CCA. In this review, we discuss the link between oxidative stress and the hepatic immune compartments, as well as how these factors trigger hepatocyte damage, proliferation, and eventually cancer initiation and its sustainment. We further give an overview of new anticancer therapies based on immunomodulation.
AU  - Leone, V.
AU  - Ali, A.*
AU  - Weber, A.*
AU  - Tschaharganeh, D.F.*
AU  - Heikenwalder, M.*
C1  - 61446
C2  - 50254
CY  - 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
SP  - 606-623
TI  - Liver inflammation and hepatobiliary cancers.
JO  - Trends Cancer
VL  - 7
IS  - 7
PB  - Cell Press
PY  - 2021
SN  - 2405-8033
ER  - 

TY  - JOUR
AB  - Diabetes has long been associated with an increased risk of cancer. While many molecular connections likely exist between the diseases, a recent publication discovered a clear molecular link, demonstrating that a glucose-dependent destabilisation of the DNA demethylase TET2 can promote-malignant transformation via an AMPK-dependent phosphoswitch.
AU  - Singh, H.R.*
AU  - Stricker, S.H.
C1  - 55097
C2  - 46094
CY  - 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
SP  - 5-7
TI  - Glucose-regulated TET2 activity links cancer to diabetes.
JO  - Trends Cancer
VL  - 5
IS  - 1
PB  - Cell Press
PY  - 2019
SN  - 2405-8033
ER  - 

TY  - JOUR
AB  - Cancer cachexia is a multifactorial condition characterized by body weight loss that negatively affects quality of life and survival of patients with cancer. Despite the clinical relevance, there is currently no defined standard of care to effectively counteract cancer-associated progressive tissue wasting. Skeletal muscle atrophy represents the main manifestation of cancer cachexia. However, cancer cachexia is increasingly seen as a systemic phenomenon affecting and/or influenced by various organs. Here, we describe recent developments elucidating the roles of different tissues as well as tissue crosstalk in this wasting syndrome, including potential links to other cancer-associated morbidities. A more comprehensive understanding of cancer cachexia etiology and heterogeneity may enable the development of intervention strategies to prevent or reverse this devastating condition.
AU  - Schmidt, S.F.
AU  - Rohm, M.
AU  - Herzig, S.
AU  - Berriel Diaz, M.
C1  - 54631
C2  - 45729
CY  - 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
SP  - 849-860
TI  - Cancer cachexia: More than skeletal muscle wasting.
JO  - Trends Cancer
VL  - 4
IS  - 12
PB  - Cell Press
PY  - 2018
SN  - 2405-8033
ER  -